Company: BIAF
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001493152-25-023405
Chunk: 42

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 8
Chunk 42
---
iation
and amortization expenses totaled approximately $113,000 and $151,000 for the three months ended September 30, 2025 and 2024, respectively.
The decrease of approximately $38,000, or 25%, for the three months ended September 30, 2025, compared to the same period in 2024 was
primarily attributable to the termination of a financing lease in April 2025 due to the Company’s targeted strategic actions announced
in March, 2025.

Other
Income (Expense)

    Three
    Months Ended  
    Change
    in 2025 

    September
    30,  
    Versus
    2024 

    2025  
    2024  
    $  
    % 
  
    Interest (expense)
    income, net 
    $(4,270) 
    $(19,403) 
    $15,133  
     78%
  
    Other income (expense),
    net 
     (3,326) 
     (5,014) 
     1,688  
     34%
  
    Gain
    (loss) on remeasurement of warrant liabilities 
     (2,747,460) 
     —  
     (2,747,460) 
     —%
  
    Total
    other (expense) income 
    $(2,755,056) 
    $(24,417) 
    $(2,730,639) 
     11,183%

Total
other income (expense), net totaled ($2.8 million) and approximately ($24,000) for the three months ended September 30, 2025 and 2024,
respectively. The increase in the total other expenses of approximately $2.7 million is mostly attributable to the remeasurement of warrant
liability, which was reclassified as equity after completion of certain events which prevented for equity classification.

Nine
Months Ended September 30, 2025, Compared to Nine Months Ended September 30, 2024

Net
loss for the nine months ended September 30, 2025, was approximately $11.8 million, compared to a net loss of approximately $6.0 million
for the nine months ended September 30, 2024.

23

Revenue

Since
acquisition of the clinical pathology laboratory on September 19, 2023, additional